Earnings highlights source yahoo
As of December 31, 2019, AIM had cash, cash equivalents and marketable securities of $8.778 million, compared with $1.825 million as of December 31, 2018.
Research and development expenses for 2019 were $4.651 million, compared with $4.778 million for 2018. General and administrative expenses for 2019 were $7.039 million,...
I cleaned up on this one. I got a little antsy because Robinhood has not let me trade for a week, but today was redemption. I jumped in, and gambled on the curve. Made a quick profit. I'm out for the day guys.
AIM = WEDGE SISTEM MONTER VOLUME = CORONA VIRUS PLAYERS = SPONSOR OF TRUMP ILLUSIONISM FOR HEL CORONAVIRUS.. STAY TUNED FROM 1.3$ to 15$ from today to May 15th
IM IN FROM YESTERDAY 5000
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated,...
DISCLAIMER. This post is for educational purposes only and should not be construed as investment advice. Your use of the stock observations is entirely at your own risk and it is your sole responsibility
AIM
Has a Gap to fill & seen big unsual buying. Has a very Low float.
A Biotech stock targeting diffrent cancers, a lot of data due throughout 2020
- Triple-Negative Breast Cancer ; Phase 1 data due 2Q
- Colorectal cancer ; Phase 2 date due 2Q
- Ovarian cancer ; Phase 1 interim data due 1Q
- Ovarian cancer ; Phase 2 data due 4Q
